Cargando…
Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
Background Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder that increases the risk of developing benign and malignant tumors. Several associated endocrine diseases in NF-1 patients have been explained in the literature. Thus, this study aims to assess the endocrine...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110103/ https://www.ncbi.nlm.nih.gov/pubmed/35586386 http://dx.doi.org/10.1055/s-0041-1742197 |
_version_ | 1784709027191586816 |
---|---|
author | Alshahrani, Aysha Abuoliat, Zainah Alshahrani, Awad Saad Al Balwi, Mohammed Ali |
author_facet | Alshahrani, Aysha Abuoliat, Zainah Alshahrani, Awad Saad Al Balwi, Mohammed Ali |
author_sort | Alshahrani, Aysha |
collection | PubMed |
description | Background Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder that increases the risk of developing benign and malignant tumors. Several associated endocrine diseases in NF-1 patients have been explained in the literature. Thus, this study aims to assess the endocrine manifestations as there no previous local data have discussed this association. Methods A retrospective cross-sectional study was conducted at KAMC and KASCH, Riyadh, Saudi Arabia by including all patients genetically confirmed with NF1 from 2004 until 2019 using a consecutive non-probability sampling technique. The included data were demographics, consanguinity, genetic variant mutations as well as associated endocrine diseases. Results The prevalence of patients with associated endocrine diseases was estimated to be 19.4%. Short stature showed the highest frequency of associated endocrine diseases followed by subclinical hypothyroidism. Positive consanguinity, sporadic mutation, and pathogenic variant showed high frequencies. Conclusion The coexistence of endocrine diseases was found in NF-1 patients. Therefore, screening for endocrine abnormality in patients with NF-1 by comprehensive history and physical exam as well as investigations to minimize complications and the late presentation should be considered; however, further studies are necessary to address the need. |
format | Online Article Text |
id | pubmed-9110103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91101032022-05-17 Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 Alshahrani, Aysha Abuoliat, Zainah Alshahrani, Awad Saad Al Balwi, Mohammed Ali Avicenna J Med Background Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder that increases the risk of developing benign and malignant tumors. Several associated endocrine diseases in NF-1 patients have been explained in the literature. Thus, this study aims to assess the endocrine manifestations as there no previous local data have discussed this association. Methods A retrospective cross-sectional study was conducted at KAMC and KASCH, Riyadh, Saudi Arabia by including all patients genetically confirmed with NF1 from 2004 until 2019 using a consecutive non-probability sampling technique. The included data were demographics, consanguinity, genetic variant mutations as well as associated endocrine diseases. Results The prevalence of patients with associated endocrine diseases was estimated to be 19.4%. Short stature showed the highest frequency of associated endocrine diseases followed by subclinical hypothyroidism. Positive consanguinity, sporadic mutation, and pathogenic variant showed high frequencies. Conclusion The coexistence of endocrine diseases was found in NF-1 patients. Therefore, screening for endocrine abnormality in patients with NF-1 by comprehensive history and physical exam as well as investigations to minimize complications and the late presentation should be considered; however, further studies are necessary to address the need. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-02-18 /pmc/articles/PMC9110103/ /pubmed/35586386 http://dx.doi.org/10.1055/s-0041-1742197 Text en Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Alshahrani, Aysha Abuoliat, Zainah Alshahrani, Awad Saad Al Balwi, Mohammed Ali Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 |
title | Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 |
title_full | Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 |
title_fullStr | Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 |
title_full_unstemmed | Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 |
title_short | Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 |
title_sort | prevalence of associated endocrine diseases in patients with neurofibromatosis type 1 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110103/ https://www.ncbi.nlm.nih.gov/pubmed/35586386 http://dx.doi.org/10.1055/s-0041-1742197 |
work_keys_str_mv | AT alshahraniaysha prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1 AT abuoliatzainah prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1 AT alshahraniawadsaad prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1 AT albalwimohammedali prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1 |